- Home
- About Us
- Service
- Application
- Technology
- Contact Us
HapOnco® Core Panel
HapOnco® Core Panel
Clinical 136 - Gene Testing
Product Introduction
HapOnco® CorePanel Clinical 136 - Gene Testing is a gene testing product independently developed by HaploX based on high - throughput target region capture technology. The testing content includes 136 genes closely related to lung cancer, gastrointestinal tumors, hepatopancreatobiliary tumors, breast cancer, gynecological tumors, urinary system tumors, and central nervous system tumors. It evaluates from the aspects of targeted therapy, immunotherapy, chemotherapy, and heredity, and analyzes the drug sensitivity and resistance of tumor patients in multiple dimensions.
Product Advantages
(1) Focused testing scope: Concentrating on targeted therapy to evaluate the efficacy of various tumor drugs;
(2) Accurate sequencing and analysis technology: Ensuring the effective detection of low - frequency mutations and avoiding false negatives.
Applicable Population
Newly diagnosed patients requiring molecular subtyping
Patients planning to under-go targeted therapy,immunotherapy, or chemotherap
patients needing prognosis assessment and efficacy prediction
Patients with drug resistance or poor response to traditional treatments, seeking additional treatment options
Applicable Cancer Types
Lung Cancer
Gastrointestinal Tumors
Hepatopancreatobiliary Tumors
Breast Cancer
Gynecological Tumors
Urinary System Tumors
Central Nervous System Tumors
Address
Units 610, 6/F, Building 16W, Phase 3, HongKong Science Park, New Territories, HongKong
Phone
+852 69410851
customer_service@haplox.net
© 2025 HaploX Ltd. All Rights Reserved.
